01/13/21 7:03 PMNasdaq : PRVBProvention Bio Announces Pricing of $100 Million Public Offering of Common StockProvention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pricing of its previously announced underwritten public offering of 6,250,000 shares of its commonRHEA-AIneutral
01/12/21 4:26 PMNasdaq : PRVBProvention Bio Announces Proposed Public Offering of Common StockProvention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. All of theRHEA-AIneutral
01/06/21 4:05 PMNasdaq : PRVBProvention Bio to Participate in the H.C. Wainwright Virtual BioConnect ConferenceProvention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the H.C. Wainwright BioConnect 2021RHEA-AIneutral
01/04/21 7:00 AMNasdaq : PRVBProvention Bio Announces U.S. FDA Filing of a Biologics License Application (BLA) and Priority Review for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk IndividualsProvention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the Biologics License Application (BLA) for teplizumab for the delay or prevention of clinical type 1RHEA-AIneutral
12/21/20 7:30 AMNasdaq : PRVBProvention Bio Announces Addition to NASDAQ Biotechnology IndexProvention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market openRHEA-AIneutral
12/15/20 7:30 AMNasdaq : PRVBProvention Bio Initiates First-in-Human Study of Coxsackievirus B Vaccine Candidate PRV-101Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the initiation of PROVENT ( PRO tocol for coxsackievirus V accin E in healthy volu NT eers), aRHEA-AInegative
12/08/20 8:55 AMNasdaq : PRVBJDRF Launches First Mass Screening Program for Early-Stage Type 1 Diabetes (T1D) DetectionOn the heels of National Diabetes Awareness Month, JDRF, the leading global funder of type 1 diabetes (T1D) research, has launched a groundbreaking screening initiative for T1D: T1Detect. Designed to make early detection of T1D easier andRHEA-AIneutral
11/11/20 7:30 AMNasdaq : PRVBProvention Bio to Present at the Stifel Virtual Healthcare ConferenceProvention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that management will present at the Stifel Virtual Healthcare Conference on Wednesday, November 18, 2020, atRHEA-AIneutral
11/05/20 7:00 AMNasdaq : PRVBProvention Bio Reports Third Quarter 2020 Financial Results and Provides Business UpdateProvention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today reported financial results for the third quarter ended September 30, 2020, and provided a business update."We areRHEA-AIneutral
11/02/20 7:30 AMNasdaq : PRVBProvention Bio Completes Rolling Submission of the Biologics License Application (BLA) for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk IndividualsProvention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced the completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and DrugRHEA-AIneutral